NCT01719419

Brief Summary

The purpose of this study is to determine if the drug orlistat (Alli, Xenical) decreases the taste for fat in humans.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 30, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 1, 2012

Completed
Last Updated

December 18, 2015

Status Verified

December 1, 2015

Enrollment Period

6 months

First QC Date

October 30, 2012

Last Update Submit

December 17, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Does orlistat decreases the taste for fatty food intake

    * Before eating, you will be given instructions on how to use the study medication. You will swish about 2 teaspoons of a solution in your mouth for 30 seconds and then spit it out (like mouthwash). * Just before eating, you will be given another brief questionnaire judging your appetite. * You will be given the test meal. You will be allowed to eat as much or as little as you like during a 20-minute eating period. * 30 minutes after starting your meal you will be given the brief questionnaire again to judge your appetite. * You will return in 1 month to complete test visit 2.

    1 month

Study Arms (2)

Placebo

EXPERIMENTAL

Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.

Drug: Placebo

Orlistat

EXPERIMENTAL

Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.

Drug: Orlistat

Interventions

Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.

Placebo

Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.

Orlistat

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Are a healthy male or female,
  • Are between 18 to 70 years of age,
  • Have a body mass index between 25-35 kg/m2

You may not qualify if:

  • Are a female who is pregnant or nursing,
  • Are a restrained eater (determined using a questionnaire),
  • Have any current illnesses such as an infection,
  • Have any serious medical problems including kidney, liver, heart or lung disease,
  • Use medications known to increase appetite,
  • Are taking any medication that has not been on the same dose for at least 30 days,
  • Dislike the test food.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

Location

MeSH Terms

Conditions

Overweight

Interventions

Orlistat

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

LactonesOrganic Chemicals
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigaator

Study Record Dates

First Submitted

October 30, 2012

First Posted

November 1, 2012

Study Start

March 1, 2012

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

December 18, 2015

Record last verified: 2015-12

Locations